Long-term outcome of major depressive disorder in psychiatric patients is variable

被引:94
|
作者
Holma, K. Mikael [1 ,2 ]
Holma, Irina. A. K. [1 ,2 ]
Melartin, Tarji K. [2 ,3 ]
Rytsala, Heikki J. [2 ,3 ]
Isometsa, Erkki T. [1 ,2 ]
机构
[1] Univ Helsinki, Cent Hosp, Dept Psychiat, Helsinki, Finland
[2] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland
[3] HUCH, Peijas Hosp, Healthcare Dist Helsinki & Uusimaa, Vantaa, Finland
关键词
D O I
10.4088/JCP.v69n0205
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: The prevailing view of outcome of major depressive disorder (MDD), based on mostly inpatient cohorts sampled from tertiary centers, emphasizes chronicity and frequent recurrences. We investigated the long-term outcome of a regionally representative psychiatric MDD cohort comprising mainly outpatients. Method: The Vantaa Depression Study included 163 patients with DSM-IV MDD (71.5% of those eligible) diagnosed using structured and semistructured interviews and followed up at 6 months, 18 months, and 5 years with a life chart between February 1, 1997, and April 30, 2004. The effects of comorbid disorders and other predictors on outcome were comprehensively investigated. Results: Over the 5-year follow-up, 98.8% of patients achieved a symptom state below major depressive episode (MDE) criteria, and 88.4% reached full remission, with the median time to full remission being 11.0 months. Nearly one third (29.3%) had no recurrences, whereas 30.0% experienced 1, 12.9% experienced 2, and 27.9% experienced 3 or more recurrences. Preceding dysthymic disorder (p = .028), cluster C personality disorder (p = .041), and longer MDE duration prior to entry (p = .011) were the most significant predictors of longer time in achieving full remission. Severity of MDD and comorbidity, especially social phobia, predicted probability of, shorter time to, and number of recurrences. Conclusion: Previous literature on mostly inpatient MDD may have, by generalizing from patients with the most severe psychopathology, overemphasized chronicity of MDD. The longterm outcome of MDD in psychiatric care is variable, with about one tenth of patients having poor, one third having intermediate, and one half having favorable outcomes. In addition to known predictors, cluster C personality disorders and social phobia warrant further attention as predictors of MDD outcome among outpatients.
引用
收藏
页码:196 / 205
页数:10
相关论文
共 50 条
  • [1] Long-term outcome of major depressive disorder in psychiatric patients is variable
    Isometsa, E. T.
    Holma, K. M.
    Holma, I. A. K.
    Melartin, T. K.
    Rytsala, H. J.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2008, 107 : S55 - S56
  • [2] DURATION OF UNTREATED ILLNESS AND LONG-TERM OUTCOME IN MAJOR DEPRESSIVE DISORDER
    Primavera, D.
    Cosso, F.
    Sanna, L.
    Bandecchi, C.
    Lepori, T.
    Carpiniello, B.
    [J]. EUROPEAN PSYCHIATRY, 2012, 27
  • [3] Escitalopram in the long-term treatment of major depressive disorder in elderly patients
    Kasper, S.
    Lemming, O. M.
    de Swart, H.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S233 - S233
  • [4] Escitalopram in the long-term treatment of major depressive disorder in elderly patients
    Kasper, Siegfried
    Lemming, Ole Michael
    de Swart, Hans
    [J]. NEUROPSYCHOBIOLOGY, 2006, 54 (03) : 152 - 159
  • [5] Long-Term Benzodiazepine Use in Patients With Major Depressive Disorder in China
    Li, You-Hong
    Xiang, Yu-Tao
    Su, Yun-Ai
    Shu, Liang
    Yu, Xin
    Kilbourne, Amy M.
    Ungvari, Gabor S.
    Chiu, Helen F. K.
    Ma, Cui
    Wang, Gao-Hua
    Bai, Pei-Shen
    Liu, Xie-He
    Sun, Li-Zhong
    Shi, Jian-Guo
    Chen, Xian-Sheng
    Mei, Qi-Yi
    Li, Ke-Qing
    Si, Tian-Mei
    [J]. PERSPECTIVES IN PSYCHIATRIC CARE, 2014, 50 (03) : 149 - 154
  • [6] Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
    Vieta, Eduard
    Loft, Henrik
    Florea, Ioana
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (09) : 877 - 884
  • [7] Duloxetine in the long-term treatment of major depressive disorder
    Raskin, J
    Goldstein, DJ
    Mallinckrodt, CH
    Ferguson, MB
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1237 - 1244
  • [8] LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH PAROXETINE
    DUBOFF, EA
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1993, 13 (06) : S28 - S33
  • [9] fMRI markers for the prediction of short- and long-term outcome in major depressive disorder
    Ruhe, H. G.
    Rive, M. M.
    Geugies, H.
    Schmaal, L.
    Van Tol, M. J.
    Opmeer, E. M.
    Marquand, A. F.
    Van der Wee, N. J.
    Penninx, B.
    Schene, A. H.
    Veltman, D. J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S130 - S130
  • [10] Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder
    Baethge, C
    Gruschka, P
    Smolka, MN
    Berghöfer, A
    Bschor, T
    Müller-Oerlinghausen, B
    Bauer, M
    [J]. JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2003, 28 (05): : 355 - 361